UPB (Upstream Bio) Gross-Profit-to-Asset % : 0.69% (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Upstream Bio Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Upstream Bio's annualized Gross Profit for the quarter that ended in Dec. 2024 was $2.45 Mil. Upstream Bio's average Total Assets over the quarter that ended in Dec. 2024 was $357.21 Mil. Therefore, Upstream Bio's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 0.69%.

Upstream Bio Gross-Profit-to-Asset % Historical Data

The historical data trend for Upstream Bio's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Upstream Bio Gross-Profit-to-Asset % Chart

Upstream Bio Annual Data

Trend

Dec22

Dec23

Dec24

Gross-Profit-to-Asset %

6.56

3.51

0.79

Upstream Bio Quarterly Data
	Dec22	Sep23	Dec23	Jun24	Sep24	Dec24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial			13.44	1.54	-	1.02	0.69

Competitive Comparison of Upstream Bio's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Upstream Bio's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Upstream Bio's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Upstream Bio's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Upstream Bio's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

Upstream Bio Gross-Profit-to-Asset % Calculation

Upstream Bio's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2024 )	/	( (Total Assets (A: Dec. 2023 )	+	Total Assets (A: Dec. 2024 ))	/ count )
	=	2.37	/	( (117.198	+	481.719)	/ 2 )
	=	2.37	/	299.4585
	=	0.79 %

Upstream Bio's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	2.452	/	( (232.7	+	481.719)	/ 2 )
	=	2.452	/	357.2095
	=	0.69 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Upstream Bio Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Upstream Bio's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Upstream Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

890 Winter Street, Suite 200, Waltham, MA, USA, 02451

Website

https://www.upstreambio.com

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.